338 related articles for article (PubMed ID: 30352235)
1. Evaluating the abilities of diverse nitroaromatic prodrug metabolites to exit a model Gram negative vector for bacterial-directed enzyme-prodrug therapy.
Chan-Hyams JVE; Copp JN; Smaill JB; Patterson AV; Ackerley DF
Biochem Pharmacol; 2018 Dec; 158():192-200. PubMed ID: 30352235
[TBL] [Abstract][Full Text] [Related]
2. Protocol for evaluating the abilities of diverse nitroaromatic prodrug metabolites to exit a model Gram negative bacterial vector.
Chan-Hyams JVE; Ackerley DF
MethodsX; 2020; 7():100797. PubMed ID: 32021829
[TBL] [Abstract][Full Text] [Related]
3. Creation and screening of a multi-family bacterial oxidoreductase library to discover novel nitroreductases that efficiently activate the bioreductive prodrugs CB1954 and PR-104A.
Prosser GA; Copp JN; Mowday AM; Guise CP; Syddall SP; Williams EM; Horvat CN; Swe PM; Ashoorzadeh A; Denny WA; Smaill JB; Patterson AV; Ackerley DF
Biochem Pharmacol; 2013 Apr; 85(8):1091-103. PubMed ID: 23399641
[TBL] [Abstract][Full Text] [Related]
4. Pseudomonas aeruginosa NfsB and nitro-CBI-DEI--a promising enzyme/prodrug combination for gene directed enzyme prodrug therapy.
Green LK; Syddall SP; Carlin KM; Bell GD; Guise CP; Mowday AM; Hay MP; Smaill JB; Patterson AV; Ackerley DF
Mol Cancer; 2013 Jun; 12():58. PubMed ID: 23758947
[TBL] [Abstract][Full Text] [Related]
5. Engineering the
Sharrock AV; McManaway SP; Rich MH; Mumm JS; Hermans IF; Tercel M; Pruijn FB; Ackerley DF
Front Pharmacol; 2021; 12():701456. PubMed ID: 34163368
[TBL] [Abstract][Full Text] [Related]
6. Discovery and evaluation of Escherichia coli nitroreductases that activate the anti-cancer prodrug CB1954.
Prosser GA; Copp JN; Syddall SP; Williams EM; Smaill JB; Wilson WR; Patterson AV; Ackerley DF
Biochem Pharmacol; 2010 Mar; 79(5):678-87. PubMed ID: 19852945
[TBL] [Abstract][Full Text] [Related]
7. The Flavin Reductase MsuE Is a Novel Nitroreductase that Can Efficiently Activate Two Promising Next-Generation Prodrugs for Gene-Directed Enzyme Prodrug Therapy.
Green LK; Storey MA; Williams EM; Patterson AV; Smaill JB; Copp JN; Ackerley DF
Cancers (Basel); 2013 Aug; 5(3):985-97. PubMed ID: 24202330
[TBL] [Abstract][Full Text] [Related]
8. The bystander effect of the nitroreductase/CB1954 enzyme/prodrug system is due to a cell-permeable metabolite.
Bridgewater JA; Knox RJ; Pitts JD; Collins MK; Springer CJ
Hum Gene Ther; 1997 Apr; 8(6):709-17. PubMed ID: 9113510
[TBL] [Abstract][Full Text] [Related]
9. Engineering a Multifunctional Nitroreductase for Improved Activation of Prodrugs and PET Probes for Cancer Gene Therapy.
Copp JN; Mowday AM; Williams EM; Guise CP; Ashoorzadeh A; Sharrock AV; Flanagan JU; Smaill JB; Patterson AV; Ackerley DF
Cell Chem Biol; 2017 Mar; 24(3):391-403. PubMed ID: 28262557
[TBL] [Abstract][Full Text] [Related]
10. Studies on the nitroreductase prodrug-activating system. Crystal structures of complexes with the inhibitor dicoumarol and dinitrobenzamide prodrugs and of the enzyme active form.
Johansson E; Parkinson GN; Denny WA; Neidle S
J Med Chem; 2003 Sep; 46(19):4009-20. PubMed ID: 12954054
[TBL] [Abstract][Full Text] [Related]
11. E. coli nitroreductase/CB1954 gene-directed enzyme prodrug therapy: role of arylamine N-acetlytransferase 2.
Mitchell DJ; Minchin RF
Cancer Gene Ther; 2008 Nov; 15(11):758-64. PubMed ID: 18600257
[TBL] [Abstract][Full Text] [Related]
12. E. coli NfsA: an alternative nitroreductase for prodrug activation gene therapy in combination with CB1954.
Vass SO; Jarrom D; Wilson WR; Hyde EI; Searle PF
Br J Cancer; 2009 Jun; 100(12):1903-11. PubMed ID: 19455141
[TBL] [Abstract][Full Text] [Related]
13. 2-Amino metabolites are key mediators of CB 1954 and SN 23862 bystander effects in nitroreductase GDEPT.
Helsby NA; Ferry DM; Patterson AV; Pullen SM; Wilson WR
Br J Cancer; 2004 Mar; 90(5):1084-92. PubMed ID: 14997211
[TBL] [Abstract][Full Text] [Related]
14. Nitroreductase gene-directed enzyme prodrug therapy: insights and advances toward clinical utility.
Williams EM; Little RF; Mowday AM; Rich MH; Chan-Hyams JV; Copp JN; Smaill JB; Patterson AV; Ackerley DF
Biochem J; 2015 Oct; 471(2):131-53. PubMed ID: 26431849
[TBL] [Abstract][Full Text] [Related]
15. Identification of novel nitroreductases from Bacillus cereus and their interaction with the CB1954 prodrug.
Gwenin VV; Poornima P; Halliwell J; Ball P; Robinson G; Gwenin CD
Biochem Pharmacol; 2015 Dec; 98(3):392-402. PubMed ID: 26415543
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and evaluation of nitroheterocyclic carbamate prodrugs for use with nitroreductase-mediated gene-directed enzyme prodrug therapy.
Hay MP; Anderson RF; Ferry DM; Wilson WR; Denny WA
J Med Chem; 2003 Dec; 46(25):5533-45. PubMed ID: 14640560
[TBL] [Abstract][Full Text] [Related]
17. Mechanism of cell death induced by the novel enzyme-prodrug combination, nitroreductase/CB1954, and identification of synergism with 5-fluorouracil.
Palmer DH; Milner AE; Kerr DJ; Young LS
Br J Cancer; 2003 Sep; 89(5):944-50. PubMed ID: 12942130
[TBL] [Abstract][Full Text] [Related]
18. Sensitization of colorectal and pancreatic cancer cell lines to the prodrug 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954) by retroviral transduction and expression of the E. coli nitroreductase gene.
Green NK; Youngs DJ; Neoptolemos JP; Friedlos F; Knox RJ; Springer CJ; Anlezark GM; Michael NP; Melton RG; Ford MJ; Young LS; Kerr DJ; Searle PF
Cancer Gene Ther; 1997; 4(4):229-38. PubMed ID: 9253508
[TBL] [Abstract][Full Text] [Related]
19. Virus-directed enzyme prodrug therapy using CB1954.
Grove JI; Searle PF; Weedon SJ; Green NK; McNeish IA; Kerr DJ
Anticancer Drug Des; 1999 Dec; 14(6):461-72. PubMed ID: 10834268
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of NfsA-like nitroreductases from Neisseria meningitidis and Bartonella henselae for enzyme-prodrug therapy, targeted cellular ablation, and dinitrotoluene bioremediation.
Rich MH; Sharrock AV; Hall KR; Ackerley DF; MacKichan JK
Biotechnol Lett; 2018 Feb; 40(2):359-367. PubMed ID: 29147875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
